IGC Pharma, Inc.
IGC
$0.3262
$0.01986.46%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.98% | 41.58% | -50.99% | 77.71% | -38.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.98% | 41.58% | -50.99% | 77.71% | -38.55% |
| Cost of Revenue | 115.49% | 82.91% | -63.67% | 20.39% | -69.13% |
| Gross Profit | -21.80% | 13.79% | -36.08% | 171.43% | 30.39% |
| SG&A Expenses | -49.28% | -25.48% | 1.04% | -39.98% | 41.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.32% | -21.93% | -1.20% | -25.59% | 22.68% |
| Operating Income | 37.36% | 29.35% | -11.85% | 29.72% | -31.61% |
| Income Before Tax | 67.28% | 29.95% | -14.60% | 28.41% | -148.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 67.28% | 29.95% | -14.60% | 28.41% | -148.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 67.28% | 29.95% | -14.60% | 28.41% | -148.51% |
| EBIT | 37.36% | 29.35% | -11.85% | 29.72% | -31.61% |
| EBITDA | 39.36% | 30.78% | -12.42% | 31.13% | -34.76% |
| EPS Basic | 73.09% | 49.89% | 16.37% | 40.84% | -106.84% |
| Normalized Basic EPS | 49.48% | 50.00% | 16.53% | 41.41% | -9.81% |
| EPS Diluted | 73.09% | 49.89% | 16.37% | 40.84% | -106.84% |
| Normalized Diluted EPS | 49.48% | 50.00% | 16.53% | 41.41% | -9.81% |
| Average Basic Shares Outstanding | 21.82% | 39.97% | 37.18% | 21.06% | 20.09% |
| Average Diluted Shares Outstanding | 21.82% | 39.97% | 37.18% | 21.06% | 20.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
